TNF and inflammatory bowel disease: TDM of TNF-α inhibitors is well established in immune-mediated diseases, with guidelines such as the 2017 AGA recommendations for IBD [65] and accumulating evidence confirming its benefit in cases of nonresponse or loss of response [66–70].